Pfizer (PFE) and Moderna patent case against Bayer dismissed

Pfizer (PFE), BioNTech, and Moderna have lost their attempt to dismiss a patent infringement case brought by Bayer. The court's decision allows Bayer to pursue its claim related to the technology used in mRNA vaccines. This ruling may have implications for the patent landscape in the biopharmaceutical industry, potentially affecting how companies protect their innovations. The outcome could influence future litigation involving vaccine patents, which is valuable for investors in this sector.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.